Keyphrases
Pediatric
80%
Pediatric Cancer Patients
57%
Oncology Patients
55%
Delayed Clearance
53%
High-dose Methotrexate (HD-MTX)
53%
Young Adult Oncology
53%
Risk Factors
49%
Pediatric Oncology
47%
Oncology
26%
Vascular Anomalies
26%
Sirolimus
26%
Adverse Events
26%
Risk Priority number
26%
Transplant Patients
26%
L-asparaginase
26%
Bloodstream Infection
26%
Evaluating Risks
26%
Apologizing
26%
Clostridium Difficile Infection
26%
Inpatient Pediatrics
26%
Stem Cell Transplantation
26%
Infectious Complications
26%
Acute Lymphoblastic Leukemia
26%
Quality Improvement Effort
26%
Osteopathia Striata with Cranial Sclerosis
26%
Epileptic Encephalopathy
26%
Failure Mode Effect Analysis
26%
Phenotypic Spectrum
26%
Therapeutic Program
26%
Wilms Tumor
26%
Program Design
26%
Clinical Spectrum
26%
Uridine
26%
Failure Mode
26%
Hyperammonemia
26%
123I-MIBG
26%
Iodine-131 (131I)
26%
Central Line-associated Bloodstream Infection (CLABSI)
26%
Length of Stay
20%
Uridine Monophosphate
17%
Developmental Delay
17%
Status Epilepticus
17%
Neonatal Seizures
17%
Intellectual Disability
17%
Time to Clearance
16%
Renal Toxicity
16%
Patient Experience
13%
Adverse Outcomes
13%
Patient Quality
13%
Patient Safety
13%
Medicine and Dentistry
Childhood Cancer
100%
Pediatrics
80%
Oncology
58%
Drug Megadose
53%
Methotrexate
53%
Adolescence
53%
Infection
44%
Quality Improvement
40%
Adverse Event
31%
Bloodstream Infection
31%
Vascular Anomaly
26%
Cohort Analysis
26%
Systematic Review
26%
Uridine Phosphate
26%
Stem Cell Transplant
26%
Rapamycin
26%
Infectious Complication
26%
Infantile Spasm
26%
Developmental Delay
26%
Osteopathia striata
26%
Catheter Infection
26%
Supplementation
26%
Hyperammonemia
26%
Sclerosis
26%
Asparaginase
26%
Wilms' Tumor
26%
(3 Iodobenzyl)guanidine
26%
Status Epilepticus
26%
Acute Lymphoblastic Leukemia
26%
Iodine 131
26%
Brain Disease
26%
Neoplasm
21%
Patient Safety
15%
Genetic Screening
15%
Uridine Triacetate
13%
Adverse Outcome
13%
Patient Experience
13%
Pneumocystis Jirovecii
13%
Congenital Dyserythropoietic Anemia
13%
Biological Marker
13%
Newborn Screening
13%
Stereotypic Movement Disorder
13%
Anemia
13%
Fibroblast
13%
Pyrimidine
13%
Diseases
13%
Central Venous Catheter
11%
Infection Prevention
10%
Fatality
10%
Odds Ratio
10%